Adjuvant Abemaciclib/Ribociclib

Adjuvant Abemaciclib/Ribociclib #monarchE/NATALEE #Best Treatment for Breast cancer #CDK 4/6 -Cure

Cancer education made simple # Chandrakanth MV

Ribociclib in adjuvant HR+ breast cancer

OncBrothers: Practice-Changing Cancer Discussions

monarchE: adjuvant abemaciclib in HR+ breast cancer

NATALEE and monarchE: ribociclib and abemaciclib in HR+/HER2- breast cancer

NATALEE: ribociclib + NSAI as adjuvant treatment in patients with HR+/HER2− early breast cancer

monarchE: adjuvant abemaciclib + endocrine therapy in patients with HR+, HER2- high-risk eBC

Dr Mouabbi on the Use of Ribociclib vs Abemaciclib in HR+/HER2– Breast Cancer

monarchE: abemaciclib and adjuvant endocrine therapy for high-risk HR+ early breast cancer

Adding ribociclib to endocrine therapy shows an improvement in invasive DFS in HR+/HER2 BC patients

LEARN everything YOU need to KNOW about PALBOCICLIB, RIBOCICLIB and ABEMACICLIB || Dr Liz O'Riordan

Dr Liz O'Riordan

PALMARES-2: comparing first-line palbociclib, ribociclib, or abemaciclib in HR+/HER2- aBC

The benefits of adjuvant CDK4/6 and PARP inhibition in breast cancer

Inclusion criteria for NATALEE Trial - evaluating importance of ajuvant ribociclib #oncology #cancer

OncBrothers: Practice-Changing Cancer Discussions

Picking the right CDK 4/6 inhibitor upfront for metastatic breast cancer.

OncBrothers: Practice-Changing Cancer Discussions

Standard of care practice in Adjuvant HR+ Breast Cancer before ASCO 2023 #oncology #ASCO2023 #cancer

OncBrothers: Practice-Changing Cancer Discussions

#ESMO22 Highlights on abemaciclib + NSAI in HR+/HER2- advanced breast cancer: The MONARCH 3 study

European Society for Medical Oncology (ESMO)

Ribociclib in Early Breast Cancer | NEJM

4-year MonarchE results: increasing benefits with abemaciclib + ET for ER+/HER2- high-risk early BC

ADAPT trial: Endocrine + ribociclib vs. chemotherapy in HR+/HER2- early breast cancer

Study of Ribociclib and PDR001 in HR+ Metastatic Breast Cancer

Dana-Farber Cancer Institute